Quanterix Marks One-Year Anniversary of IPO with Key Milestones Accelerating Healthcare Disruption Ahead of Presentation at t...
January 04 2019 - 4:17PM
Business Wire
Company celebrates remarkable growth in 2018
fueled by new product launches, acceleration of ground-breaking
publications and rapid adoption of digital biomarkers in neurology
and oncology research
Quanterix Corporation (NASDAQ:QTRX), a company digitizing
biomarker analysis with the goal of advancing the science of
precision health, is marking a little over one year since becoming
a public company with significant milestones on its path toward
revolutionizing healthcare. Quanterix’ Chief Executive Officer,
President and Chairman will highlight these achievements and future
plans during a presentation at the upcoming 37th Annual J.P. Morgan
Healthcare Conference in San Francisco, CA, on Wednesday, Jan. 9,
2019 at 2 p.m., PST.
Since going public and listing on the Nasdaq on Dec. 7, 2017 –
in one of the most successful IPOs of its kind in recent years –
Quanterix has continued to achieve accelerated double-digit,
year-over-year revenue growth in each full quarter since the IPO.
This has been driven by major investments in the company’s flagship
Simoa technology, product expansion, acquisition, publications,
global commercialization and accelerating market adoption of
digital biomarkers for research.
“The past year has been rewarding for us as a company and we are
showing no signs of slowing down,” said Kevin Hrusovsky, Chief
Executive Officer, President and Chairman of Quanterix. “We are
committed to delivering on our promise of advancing the science of
precision health and driving today’s healthcare revolution forward.
Today we are empowering new advances in disease diagnosis and
monitoring, and helping drug makers develop better drugs, and
tomorrow we aspire to detect and prevent diseases before they even
take hold. We’re already making a tremendous impact in neurology
research and are now seeing incredible potential in immunoncology
and immunotherapy monitoring as well, where the ability to
determine the efficacy and toxicity of drugs earlier could save
significant healthcare costs and save lives. We’re excited to
return to J.P. Morgan to offer greater insight around our vision,
50% year-to-date growth through Q3’18, Q4’18 expectations and
progress toward our greater mission of helping battle cancer and
neurodegenerative diseases.”
Significant 2018 Achievements:
- Launched the SR-X Ultra-Sensitive
Biomarker Detection System™ in January 2018, less than one month
after public offering, offering researchers lower-cost and smaller
footprint access to Simoa technology.
- Acquired Aushon BioSystems and
successfully integrated the two companies. The acquisition included
a CLIA certified laboratory, expanding services and accelerating
entry into pharmaceutical drug trial services, as well as access to
novel immunoassay technology to which Simoa sensitivity algorithms
are being applied to deliver next-generation Simoa
capabilities.
- Initiated a collaboration with DestiNA
Genomics in an effort to transform microRNA biomarker detection,
bringing together high-specificity and ultra-sensitivity for the
first time.
- Gained unrestricted rights back for its
Simoa technology in IVD markets with the termination of a license
agreement with bioMérieux.
- Increased new publications dramatically
by 145, bringing the total to 360 (nearly 50% growth).
- Rapid adoption of proprietary
Neurofilament light chain (NfL) assay, a biomarker previously
mainly measured only in cerebral spinal fluid, but by using Simoa,
researchers have shown it can be measured in blood and correlated
to central spinal fluid (CSF) results. This advance has enabled
many novel applications critical for advancing the early detection,
treatment and prevention of neurological diseases, including
multiple sclerosis (MS); Parkinson’s disease; Alzheimer’s disease;
brain cancer; and traumatic brain injuries (TBIs).
- Invited by the FDA to present recent
progress and potential future strategy for NfL to senior agency
officials.
- Announced partnerships with Abbott Labs
for blood screening and Oncogenesis for a cervical cancer screening
test.
- Launched a test bed/early access
program for a new next-generation 10-plex Simoa planar array for
oncology research and drug development with a benchtop imager
called the SP-X™ Imaging and Analysis System.
- Increased headcount from 149 to 181
(>20%) and expanded the leadership team with the hiring of
Jackson Streeter, M.D., to lead corporate development and strategy,
formerly Chief Medical Officer and Chief Executive Officer of
Banyan Biomarkers and Dawn Mattoon, Ph.D., to lead strategic market
and assay technology, formerly Head of Product Development at a
leading antibody provider.
- Ranked number 299 on Deloitte’s
Technology Fast 500™ and received several noteworthy recognitions
for Quanterix’ Chief Executive Officer’s visionary leadership for
healthcare disruption.
- Last month was added to the Nasdaq
Biotechnology Index (NBI) as part of the annual re-ranking and
attracted additional analyst coverage.
- Was lead sponsor for Powering Precision
Health (PPH) annual summit held for the first time in Amsterdam,
now an independent, nonprofit entity.
“We are proud of these achievements as they help demonstrate the
power of our technology and the disruptive innovation Quanterix is
leading in the field of precision health,” continued Hrusovsky. “We
feel there is still enormous opportunity in front of us as we
facilitate industry collaboration, drive research advancement and
fuel growth as we pursue minimally invasive digital biomarker
disruption in oncology, neurodegeneration, immunology, infectious
disease and inflammation.
Webcast InformationTo access the live webcast of
Quanterix’ presentation at the 37th Annual J.P. Morgan Healthcare
Conference on Wednesday, Jan. 9, 2019 at 2 p.m., PST, please visit
the News & Events page within the Investors section of the
Quanterix website at www.quanterix.com. Replays of the
webcast will be available for a limited period following the
conference.
About QuanterixQuanterix is a company that’s digitizing
biomarker analysis with the goal of advancing the science of
precision health. The company’s digital health solution, Simoa, has
the potential to change the way in which healthcare is provided
today by giving researchers the ability to closely examine the
continuum from health to disease. Quanterix’ technology is designed
to enable much earlier disease detection, better prognoses and
enhanced treatment methods to improve the quality of life and
longevity of the population for generations to come. The technology
is currently being used for research applications in several
therapeutic areas, including oncology, neurology, cardiology,
inflammation and infectious disease. The company was established in
2007 and is located in Lexington, Massachusetts. For additional
Information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend" and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based
on Quanterix’ expectations and assumptions as of the date of
this press release. Each of these forward-looking statements
involves risks and uncertainties. Factors that may
cause Quanterix’ actual results to differ from those expressed
or implied in the forward-looking statements in this press release
are discussed in Quanterix’ filings with the U.S.
Securities and Exchange Commission, including the "Risk Factors"
sections contained therein. Except as required by
law, Quanterix assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190104005502/en/
Media:Julien Bradley(617)
301-9503jbradley@quanterix.comInvestor Relations:Stephen
Hrusovsky(774) 278-0496shrusovsky@quanterix.com
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Apr 2023 to Apr 2024